A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
Status:
Completed
Trial end date:
2017-10-11
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up
to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate
postpartum depression (PPD) compared to placebo injection as assessed by the change from
baseline in Hamilton Rating Scale for Depression (HAM-D) total score.